Nick Latimer
@NRLatimer
Followers
1K
Following
2K
Media
180
Statuses
2K
Prof of Health Economics at ScHARR, University of Sheffield. Member of NICE Appraisal Committee. Like cycling and have haemophilia.
Joined November 2013
I made a movie about survival analysis and #HTA! "What about a cure model?", set at Ultradrug Ltd. https://t.co/WhKdRQhv1R It's got a bit of KMunicate (@tmorris_mrc ), some stpm2 (@pclambert123, @MJRutherford9) and there's a special reward for anyone who makes it to the end
20
26
112
👩🏫 Join us at the #ISPORSummit for Prof. Nick Latimer's @NRLatimer talk on "Methods for Causal Inference Using Real-World Data " 📅 Sunday 17 November, 13:15 - 14:50. 💭 Enhance your #RWE knowledge with this insightful conversation. 🔗 https://t.co/GUsYm7DnWC
0
1
1
Cure Models for HTA: What You Need to Know Should decision-makers be more willing to use cure models? How do they work? What can go wrong? What on earth are flexible parametric non-mixture cure models??! Thanks to @MJRutherford9 for writing this with me. https://t.co/g8sUMVHIOM
link.springer.com
PharmacoEconomics - There is increasing interest in the use of cure modelling to inform health technology assessment (HTA) due to the development of new treatments that appear to offer the...
0
7
22
We are currently advertising for an early career researcher with a strong background in statistics/mathematics and an interest in Bayesian statistics and health technology assessment to join us at @SCHARRSheffield G7, fixed-term until 31 March 2028 https://t.co/bZYaR4VEJo
0
2
2
Treatment switching in randomised controlled trials: Trial design, what to adjust for, how, and reporting guidelines. The DSU’s new TSD 24 provides an update to TSD 16 – out now! https://t.co/5NgkwiQjW9
0
5
8
A publication from my doctoral work with my fantastic and inspiring supervisors Prof Nick Latimer @NRLatimer and Prof Jim Chilcott, and sponsored by the generous @wellcometrust. @SCHARRSheffield @SCHARRHEDS
#HTA #treatmentsequennces #RWD #causalinference
0
1
2
🚨 Helpful how-to evaluate treatment sequences for #HTA by @SCHARRSheffield Amy Chang @NRLatimer
@ph_economics #pharmacoeconomics
https://t.co/wjhQFYYPLQ
0
2
7
Research by @NRLatimer and colleagues shows that forcing a marginal hazard ratio to 1 does not accurately assess mean survival difference under individual-level treatment effect waning. More at https://t.co/qKhh6sHLnq.
#HEOR #HTA #harzardratio #ValueinHealth
0
7
7
If you're too busy to read 4000 words on moving data between countries, listen to my quick summary of key points in the video below. @VivekSubbiah @NRLatimer #oncology
In a new article, experts from @Roche, @sheffielduni, @UniOfYork, & Flatiron discuss transportability, offering practical insights for decision-makers & emphasizing need for clear guidelines & further research to strengthen #HTA evaluations. Read more: https://t.co/2CDBKu2xSJ
0
3
5
We are seeking leading cancer researchers to come & join us at Sheffield, in partnership with @SheffieldHosp. You'll have a package of support inc research staff, consumables & PhD(s) + access to dedicated funding opportunities through @yorkshirecancer 👉 https://t.co/OO0kzTt1iT
0
7
5
Some really great opportunities at Sheffield at the moment, including for methodologists.
📣 Join the University of Sheffield in the fight against cancer! 🎗️ We're recruiting top-notch cancer research leaders to help us create a future where more people survive and live longer. Apply now at https://t.co/xqfqAEJtEw
#Cancer #CancerResearch #oncology #epidemiology
0
3
4
📜Paper📜 in @BrainBehavior with @KRAbrams, @NRLatimer, @MichelaGuglieri, @MJRutherford9 and @Crowther_MJ. Assessing the CPRD as a data resource for DMD (and other rare disease) natural history models: ✅ Mortality ❓ Intermediate events https://t.co/V5na3yHCjM
#rarediseases
onlinelibrary.wiley.com
This study evaluated the Clinical Practice Research Datalink (CPRD) as a source of mortality and natural history data for Duchenne Muscular Dystrophy (DMD) in the UK population. This can help...
0
10
13
***Fully Funded PhD Studentships*** We have 7 @wellcometrust Studentships in Public Health Economics and Decision Science available. Check out our website for more information: https://t.co/81RaeaI8Ec Deadline: 11th December 2023
1
62
54
📣 This time next week #ISPOREurope will be in full swing. 🔗 take a look at SCHARR's full academic programme https://t.co/LCr7i8O2QG 😀 We hope you’ll pop by to see us on stand C2-021 in Hall E @ScHARRHEDS @ScHARRSheffield @ISPORorg
#ISPOR2023
0
4
1
12 days left until #HWSmethods2023 in @uni_mainz! Check out the program👇 with keynotes from @nkreif and @NRLatimer. You can still register via herbstworkshop2023@proton.me - no participation fees thanks to @DGEpi_eV, @gmdsEV, @IBSstats, @DGSMP_e_V. #EpiTwitter #StatsTwitter
1
8
6
A big day 🤩 We've also launched: 👩🏫 A free course in survival analysis on our new Youtube channel 💻 A new #Stata package called #morgana for Bayesian flexible survival analysis 🧐 An advert for a new Principal Biostatistician to join the team #Biostatistics
0
1
23
Nice summary of our session ‘EHR - a good target’ which focussed on research design and methodologies for working with EHR. Great turnout and discussion #RSS2023Conf
linkedin.com
This morning at the Royal Statistical Society Annual Conference in glorious Harrogate, the Medical Statistics stream sponsored by IJPDS is in full swing. This session is called Electronic health...
0
4
9
I'm delighted to announce publication of a new tutorial article on use of excess hazard models for HTA survival extrapolation with accompanying R and Stata code. Huge thanks to @MJRutherford9 @danj_statsguru @NRLatimer @pclambert123 and all co-authors https://t.co/2sq41tNjNz
journals.sagepub.com
Background Different parametric survival models can lead to widely discordant extrapolations and decision uncertainty in cost-effectiveness analyses. The use of...
0
7
23
A review of survival extrapolation methods with external evidence finds lots of methods, but little in the way of validation #hta #survivalanalysis
@AshBullement @gianlubaio @gemmaeshields @NRLatimer @ScHARRHEDS @stats_UCL @HealthEcon_MCR
https://t.co/F3hFcyEEfI
0
7
9
New paper just out: we tend to always use the Hazard Ratio as population-level summary measure in clinical trials with survival outcomes. Is that always justified? [1/N] @tmorris_mrc @IanWhit25399993 @MaxParmarMRCUCL
https://t.co/X6LvLlNPY9
journals.sagepub.com
Background The population-level summary measure is a key component of the estimand for clinical trials with time-to-event outcomes. This is particularly the cas...
1
27
109
We are delighted to welcome Dr Caroline Mitchell @dclovesgp as co-lead of our cancer research theme on cancer prevention & early diagnosis, with @NRLatimer. With a better understanding of cancer in Yorkshire, we can develop targeted interventions & screening to improve survival.
1
5
15